Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amrutanjan Health CareNSE:AMRUTANJAN -0.47%71 PS Ratio is 2.77 as of Sep. 15, 2026, which is 42% below its 10-year median of 4.74. GuruFocus rates NSE:AMRUTANJAN with a GF Score™ of 71/100 and a GF Value™ of ₹830.57 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Amrutanjan Health Care ranks worse than 56.65% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Amrutanjan Health Care's share price is ₹490.95.
Amrutanjan Health Care's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹176.92. Hence, Amrutanjan Health Care's PS Ratio for today is 2.77.
Good Sign:
Amrutanjan Health Care Ltd stock PS Ratio (=2.77) is close to 10-year low of 2.77.
The historical rank and industry rank for Amrutanjan Health Care's PS Ratio or its related term are showing as below:
NSE:AMRUTANJAN'
s PS Ratio Range Over the Past 10 Years
Min: 2.77 Med: 4.74 Max: 16.55
Current: 2.77
During the past 13 years, Amrutanjan Health Care's highest PS Ratio was 16.55. The lowest was 2.77. And the median was 4.74.
NSE:AMRUTANJAN's PS Ratio is ranked worse than 56.65% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.31
vs NSE:AMRUTANJAN: 2.77
During the past 12 months, the average Revenue per Share Growth Rate of Amrutanjan Health Care was 10.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 10.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 7.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 10.90% per year.
During the past 13 years, Amrutanjan Health Care's highest 3-Year average Revenue per Share Growth Rate was 19.70% per year. The lowest was 4.00% per year. And the median was 11.00% per year.
Amrutanjan Health Care (NSE:AMRUTANJAN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amrutanjan Health Care's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amrutanjan Health Care PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amrutanjan Health Care's PS Ratio distribution charts can be found below:
* The bar in red indicates where Amrutanjan Health Care's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Amrutanjan Health Care's Share Price of today is ₹490.95. Amrutanjan Health Care's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹176.92.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Amrutanjan Health Care (NSE:AMRUTANJAN) has a PS Ratio of 2.77 as of Sep. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Amrutanjan Health Care and its competitors. This is 42% below median its historical median of 4.74. Over the past decade, Amrutanjan Health Care's PS Ratio has ranged from 2.77 to 16.55. According to the industry distribution chart, Amrutanjan Health Care ranks #541 out of 955 companies in the Drug Manufacturers industry, placing it in the top 56.6%.
Is Amrutanjan Health Care's PS Ratio too high?
Amrutanjan Health Care's current PS Ratio of 2.77 is 42% below median its 10-year median of 4.74. Over the past 10 years, this metric has ranged from a low of 2.77 to a high of 16.55. The Drug Manufacturers industry median PS Ratio is 2.31. Amrutanjan Health Care's value of 2.77 is 19.9% above this industry median. Based on the distribution chart, Amrutanjan Health Care ranks #541 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amrutanjan Health Care has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amrutanjan Health Care's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Amrutanjan Health Care ranks #541 out of 955 companies for PS Ratio. This places Amrutanjan Health Care in the lower half of its industry. The industry median PS Ratio is 2.31. Amrutanjan Health Care's value of 2.77 is 19.9% above this benchmark. Historically, Amrutanjan Health Care's own PS Ratio has ranged from 2.77 to 16.55 over the past decade. While the company's 10-year median is 4.74 vs. the industry median of 2.31, Amrutanjan Health Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.31, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amrutanjan Health Care's current PS Ratio of 2.77 is 19.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Amrutanjan Health Care and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amrutanjan Health Care's current PS Ratio is 2.77, which is 42% below median its own 10-year median of 4.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amrutanjan Health Care stock overvalued right now?
Based on GuruFocus' analysis, Amrutanjan Health Care (NSE:AMRUTANJAN) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹830.57, compared to a current price of ₹490.95 — trading 40.9% below its estimated fair value. The current PS Ratio is 2.77, which is 42% below median its 10-year median of 4.74 and 19.9% above the Drug Manufacturers industry median of 2.31. Amrutanjan Health Care's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Amrutanjan Health Care (NSE:AMRUTANJAN), the current PS Ratio is 2.77 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amrutanjan Health Care (NSE:AMRUTANJAN) Overvalued in 2026?
Based on GuruFocus' analysis, Amrutanjan Health Care stock appears to be undervalued.
The current stock price of ₹490.95 is trading 40.9% below its estimated GF Value™ of ₹830.57.
GuruFocus considers Amrutanjan Health Care to be Significantly Undervalued.
Key valuation signals for NSE:AMRUTANJAN:
PS Ratio: 2.77 (42% below median its 10-year median of 4.74)
GF Value™: ₹830.57 vs. price of ₹490.95 (40.9% below fair value)
Industry Position: 19.9% above the Drug Manufacturers median (#541 of 955)
No single metric tells the full story. See the NSE:AMRUTANJAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amrutanjan Health Care Ltd manufactures Ayurvedic and allopathic products. The company operates through the following segments: OTC Products, Beverages, and Others. The majority of the revenue is generated from its OTC segment which is engaged in the manufacturing products of pain management, congestion management, and hygiene. Its beverage segment includes manufacturing fruit juices and oral rehydration drinks. Some of its products include Roll-on, Spray, Balm, Cough Syrup, Sanitary napkins, and inhalers. Geographically, it generates the majority of the revenue from India.
71GF Score
Get the complete analysis for NSE:AMRUTANJAN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AMRUTANJAN has been successfully added to your 
